Author

Ayşe Neslihan Aslan

Observed names: Aslan, Ayşe Neslihan, Ayse Neslihan Aslan

Institution: Pfizer (United States)

Observed institution: Pfizer (United States)

OpenAlex ID: A5134790751

Patient-reported Outcomes Through 12-weeks of Double-blind Rimegepant Treatment for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives (P1-15.008)

2026 · Amaal Starling, Jan Versijpt, et al. · Neurology

Rimegepant for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives: Results from a 12-week Open-label Extension Phase of a Randomized, Placebo-controlled Trial (P10-15.011)

2026 · Patricia Pozo-Rosich, Jose Gien-Lopez, et al. · Neurology

Does rimegepant prevent migraine attacks in people who have not found other treatments taken by mouth (orally) to work well? A plain language summary of clinical study findings

2026 · Pozo-Rosich, Patricia, López, José Antonio Gien, et al. · Figshare

Does rimegepant prevent migraine attacks in people who have not found other treatments taken by mouth (orally) to work well? A plain language summary of clinical study findings

2026 · Patricia Pozo-Rosich, José Antonio Gien López, et al. · Pain Management

Works count: 4

Citation count:

H-index:

I10-index: